ATE326986T1 - Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung - Google Patents

Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung

Info

Publication number
ATE326986T1
ATE326986T1 AT03718854T AT03718854T ATE326986T1 AT E326986 T1 ATE326986 T1 AT E326986T1 AT 03718854 T AT03718854 T AT 03718854T AT 03718854 T AT03718854 T AT 03718854T AT E326986 T1 ATE326986 T1 AT E326986T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
improved
vivo gene
gene transmission
formula
Prior art date
Application number
AT03718854T
Other languages
German (de)
English (en)
Inventor
Bruno Pitard
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE326986T1 publication Critical patent/ATE326986T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03718854T 2002-02-08 2003-02-07 Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung ATE326986T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0201584A FR2835749B1 (fr) 2002-02-08 2002-02-08 Composition pharmaceutique ameliorant le transfert de gene in vivo

Publications (1)

Publication Number Publication Date
ATE326986T1 true ATE326986T1 (de) 2006-06-15

Family

ID=27620039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03718854T ATE326986T1 (de) 2002-02-08 2003-02-07 Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung

Country Status (10)

Country Link
US (2) US7709452B2 (cg-RX-API-DMAC7.html)
EP (1) EP1471944B1 (cg-RX-API-DMAC7.html)
JP (1) JP4613011B2 (cg-RX-API-DMAC7.html)
AT (1) ATE326986T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003222896A1 (cg-RX-API-DMAC7.html)
CA (1) CA2473212C (cg-RX-API-DMAC7.html)
DE (1) DE60305443T2 (cg-RX-API-DMAC7.html)
ES (1) ES2265569T3 (cg-RX-API-DMAC7.html)
FR (1) FR2835749B1 (cg-RX-API-DMAC7.html)
WO (1) WO2003066104A2 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868953B1 (fr) * 2004-04-16 2006-06-30 Inst Nat Sante Rech Med Composition pour le transfert intracellulaire d'un acide nucleique.
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
DE102006051623A1 (de) 2006-11-02 2008-07-31 Horn, Peter A. Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers
EP2331071A1 (en) 2008-09-05 2011-06-15 Institut National De La Sante Et De La Recherche Medicale Novel multimodular assembly useful for intracellular delivery
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013106558A1 (en) 2012-01-10 2013-07-18 Merial Limited Lipid based adjuvants for dna - plasmid vaccines
WO2013128424A1 (en) 2012-03-02 2013-09-06 Institut National De La Sante Et De La Recherche Medicale Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US20150182620A1 (en) 2012-06-15 2015-07-02 Inserm (Institut De La Sante Et De La Recherche Medicale) Polypeptides for use in the Prophylactic Treatment of Allergic Asthma
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3125945B1 (en) * 2014-04-01 2019-09-11 Institut National de la Sante et de la Recherche Medicale (INSERM) Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna
EP3225246A1 (en) 2016-03-31 2017-10-04 Klinikum der Universität München Synthetic compound for improving efficiency of transfection
US20210000917A1 (en) 2018-03-05 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and composition for the treatment of allergic asthma
CA3131824A1 (en) * 2019-03-11 2020-09-17 Birgitte Rono Nucleic acid vaccination using neo-epitope encoding constructs
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
WO2024200831A1 (en) 2023-03-30 2024-10-03 Vivadju Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer
EP4704856A1 (en) 2023-03-30 2026-03-11 Vivadju Pvax14 nucleic acid formulated with nano-vehicle in combination with all-trans retinoic acid (atra) for activating immune pathways
WO2025129128A1 (en) 2023-12-15 2025-06-19 Vivasor, Inc. Compositions and methods for non-viral delivery of therapeutic compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470568A (en) * 1992-02-13 1995-11-28 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for cell repair
GB9216082D0 (en) * 1992-07-28 1992-09-09 Univ Nottingham Lymphatic delivery composition
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6359054B1 (en) * 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
EP1038016A2 (en) * 1997-12-16 2000-09-27 Valentis Inc. Needle-free injection of formulated nucleic acid molecules
GB9904627D0 (en) * 1999-03-02 1999-04-21 Danbiosyst Uk Polymer compositions for polynucleotide delivery
WO2001005913A1 (en) 1999-07-16 2001-01-25 Reatech Phosphor addition in gasification
WO2001008709A1 (en) * 1999-07-28 2001-02-08 Valentis, Inc. Sonoporation of tumors
AU2001238485A1 (en) 2000-02-18 2001-08-27 The Immune Response Corporation Methods and compositions for gene delivery
AU2001241958A1 (en) * 2000-03-03 2001-09-17 Valentis, Inc. Improved poloxamer and poloxamine compositions for nucleic acid delivery
DE60144338D1 (de) 2000-10-20 2011-05-12 Vical Inc Gen-abgabeformulierungen zur behandlung ischämischer zustände

Also Published As

Publication number Publication date
WO2003066104A2 (fr) 2003-08-14
US20050152870A1 (en) 2005-07-14
EP1471944B1 (fr) 2006-05-24
US8367631B2 (en) 2013-02-05
US20100179212A1 (en) 2010-07-15
US7709452B2 (en) 2010-05-04
ES2265569T3 (es) 2007-02-16
FR2835749B1 (fr) 2006-04-14
WO2003066104A3 (fr) 2004-03-25
JP2005522433A (ja) 2005-07-28
JP4613011B2 (ja) 2011-01-12
AU2003222896A1 (en) 2003-09-02
CA2473212C (fr) 2013-04-23
DE60305443D1 (de) 2006-06-29
EP1471944A2 (fr) 2004-11-03
CA2473212A1 (fr) 2003-08-14
FR2835749A1 (fr) 2003-08-15
AU2003222896A8 (en) 2003-09-02
DE60305443T2 (de) 2007-05-10

Similar Documents

Publication Publication Date Title
DE60305443D1 (de) Pharmazeutische zusammnesetzung zur verbesserten in-vivo genübertragung
BR0116004A (pt) Derivados de 6-o-carbamoil cetolida de eritromicina úteis como antibacterianos
BR0213802A (pt) Copolìmero útil para a preparação de géis de ácidos
SE0300010D0 (sv) Novel Compounds
ATE551988T1 (de) Orale zusammensetzungen, ihre herstellung und verwendung
EP1661905A4 (en) NEW SYNTHETIC NUCLEIC ACIDS OF TYPE WITH CROSS-LINKED N-O-BINDING
WO2006048330A8 (en) 11βετα-hsd1 inhibitors
EP1798231A3 (fr) Produits intermédiaires dans la préparation de composés anti-bactériens
CA2349227A1 (en) Substituted 2-phenylbenzimidazoles, the production thereof and their use
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
WO2007089330A3 (en) Extreme environment surfactant compositions comprising hydrolysis resistant organomodified disiloxane surfactants
SG151249A1 (en) 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
ATE420357T1 (de) Nanopartikel-polyanion-konjugate sowie verfahren zur verwendung davon beim nachweis von analyten
JP2005522433A5 (cg-RX-API-DMAC7.html)
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
CA2379026A1 (en) Substituted thiene-3-yl-sulphonylamino(thio)carbonyl-triazolin(thi)ones
ATE411362T1 (de) Gemisch von fluorierten polyethern und verwendung davon als grenzflächenaktives mittel
BR0208741A (pt) Derivados de piperidina
TW200604158A (en) New sulphur compounds: use as transfer agents for controlled radical polymerisation of acrylic acid, polymers obtained and applications thereof
BG105736A (en) 2,3,4,5-tetrahydro-1h-[1,4]benzodiasepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
BRPI0211191B8 (pt) ensaios baseados em ácido nucléico para se diagnosticar precisamente infecção por parvovírus b19 e inciadores e marcadores para uso nesses ensaios
TNSN06405A1 (en) Quinazolinone derivatives useful as vanilloid antagonistes
DK0680257T3 (da) Stabile, væskeformige sammensætninger og deres anvendelse
DE50209545D1 (de) Flüssigkristallines medium
ATE414711T1 (de) Polymerstabilisierte proteinasen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties